New fluoroquinolones in urology
Abstract
The authors review the practice of using fluoroquinolones (FQ) of the second generation in urology: levofloxacine, sparfloxacine, moxifloxacine. Details are given on chemical structure of FQ, their antimicrobial spectrum, indications for FQ administration, pharmacokinetics, efficacy in complicated infections of the urinary tracts. Treatment with new FQ demonstrated a good effect: high clinical and bacteriological responses (100 and 98.5%; 88.7 and 78.1%, 95.7 and 85.7% in the treatment with levofloxacine, sparfloxacine, moxifloxacine, respectively). The area of clinical application of FQ is urinary infection, urogenital infections, sexually transmitted diseases.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.